B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

In this preclinical study, the potential applicability of an anti-B7-1 immunotoxin (IT) for the treatment of Hodgkin's disease (HD) was investigated. Immunohistochemical analysis demonstrated strong expression of B7-1 on Hodgkin and Reed-Sternberg (R-S) cells and clear expression on dendritic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vooijs, W. C., Otten, H. G., van Vliet, M., van Dijk, A. J., de Weger, R. A., de Boer, M., Bohlen, H., Bolognesi, A., Polito, L., de Gast, G. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228107/
https://www.ncbi.nlm.nih.gov/pubmed/9365164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228107/
https://www.ncbi.nlm.nih.gov/pubmed/9365164

Ejemplares similares